期刊
JOURNAL OF CLINICAL PSYCHIATRY
卷 72, 期 6, 页码 757-764出版社
PHYSICIANS POSTGRADUATE PRESS
DOI: 10.4088/JCP.11m06837
关键词
-
资金
- Bristol-Myers Squibb
- Cephalon
- Corcept Therapeutics
- Cyberonics
- Eli Lilly
- Forest
- GlaxoSmithKline
- Janssen
- Merck
- National Institute of Mental Health (NIMH) [N01MH90003]
- National Alliance for Research in Schizophrenia and Depression (NARSAD)
- Novartis
- Pfizer
- Pharmacia Upjohn
- Predix
- Solvay
- Wyeth-Ayerst
- Abbott
- Alkermes
- Aspect Medical Systems
- AstraZeneca
- BioResearch
- BrainCells
- CeNeRx BioPharma
- Clinical Trials Solutions
- Clintara
- Covidien
- EnVivo Pharmaceuticals
- Euthymics Bioscience
- Ganeden Biotech
- Icon Clinical Research
- i3 Innovus/Ingenix
- Johnson & Johnson Pharmaceutical Research Development
- Lichtwer Pharma GmbH
- Lorex
- National Center for Complementary and Alternative Medicine
- National Institute of Drug Abuse (NIDA)
- Novartis AG
- Organon
- PamLab
- Pharmavite
- Photothera
- Roche
- RCT Logic
- Sanofi-Aventis
- Shire
- Synthelabo
- Northwestern Memorial Hospital Women's Board
- Evergreen Invitational Award
- Educational Foundation of America
- American Foundation of Suicide Prevention
- Brain Research Foundation
- American Psychological Association
- Agency for Healthcare Research and Quality
- Wyss Institute for Biologically Inspired Engineering
- Robert Wood Johnson Foundation
- M-3 Corporation
- Ovation
- Stanley Medical Research Institute
- Magstim
- Advanced Neuromodulation Systems
- Veterans Affairs Cooperative Studies Program
- American Foundation for Suicide Prevention
- Best Practice Project Management
- Brain Resource
- Bristol-Myers Squibb/Otsuka
- Gerson Lehrman Group
- Jazz
- Magellan Health Services
- Neuronetics
- Ono
- Otsuka
- University of Michigan
- Transcept
- Urban Institute
Objective: Monitoring suicidality and risk following initiation of antidepressant treatment is an essential component of clinical care, but few brief, reliable ratings of suicidal ideation and behavior in adults are available. This report evaluates the psychometric properties of a brief self- and clinician-rated measure of factors related to the risk of suicide attempt or completion. Method: Adult outpatients with nonpsychotic major depressive disorder (MDD) (n =240) were enrolled from July 2007 through February 2008 and treated in an 8-week, open-label trial with the clinician's choice of a selective serotonin reuptake inhibitor at 6 primary care and 9 psychiatric clinical care settings in the National Institute of Mental Health-funded Depression Trials Network. Diagnosis of MDD was determined by the Psychiatric Diagnostic Screening Questionnaire and an MDD checklist based on DSM-IV-TR criteria. Suicidal ideation and behavior are 1 of 9 symptoms of MDD (depressed mood, loss of interest, appetite or weight change, sleep disturbance, reduced concentration or indecisiveness, fatigue or decreased energy, psychomotor agitation or retardation, feelings of worthlessness, or excessive guilt). The newly developed Concise Health Risk Tracking (CHRT) scale was administered both as the CHRT Self-Report (CHRT-SR) and Clinician Rating (CHRT-C) scales. Psychometric evaluations were conducted on both scales. Results: The internal consistency (Cronbach alpha) was .77 for the 7-item CHRT-C and .78 for the 7-item CHRT-SR with a consistent factor structure, and 3 independent factors (current suicidal thoughts and plans, perceived lack of social support, and hopelessness) for both versions. Conclusions: The 7-item CHRT-C and the 7-item CHRT-SR have excellent psychometric properties and can be used to monitor suicidal risk in clinical practice and research settings. Whether either scale will predict suicide attempts or completions in actual practice would require a very large prospective study sample.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据